Biotechnology Bristol Myers’ $14B Bet On Schizophrenia – Drug Cuts Symptoms Without Common Side Effect Of Weight Gain Associated With Other Antipsychotics – Bristol-Myers Squibb (NYSE:BMY) Read more
Stockmarkets Teva, Viatris win new chance to challenge J&J schizophrenia drug patent Reuters via biedexmarkets.com Read more